DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Integrilin (Eptifibatide) - Summary

 
 



INTEGRILIN SUMMARY

Eptifibatide is a cyclic heptapeptide containing six amino acids and one mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties.

INTEGRILIN is indicated:

  • For the treatment of patients with acute coronary syndrome (unstable angina/non-ST-segment elevation myocardial infarction) including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). In this setting, INTEGRILIN has been shown to decrease the rate of a combined endpoint of death or new myocardial infarction.
  • For the treatment of patients undergoing PCI, including those undergoing intracoronary stenting. In this setting, INTEGRILIN has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction, or need for urgent intervention.

See all Integrilin indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Integrilin (Eptifibatide)

Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis. [2015]
Albumin in Acute Stroke Part 2 and Interventional Management of Stroke III... CONCLUSION: r-tPA plus eptifibatide showed a favorable direction of effect that

A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke. [2014]
Disorders and Stroke (NINDS) trial... CONCLUSIONS: The safety and direction of effect of eptifibatide plus rt-PA were

Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. [2011.02.22]
CONCLUSIONS: Routine early eptifibatide use, compared with delayed provisional use, may be associated with lower 30-day ischemic risk in non-ST-elevation acute coronary syndrome patients also treated with clopidogrel before angiography. The benefit-risk ratio of intensive platelet inhibition with combined early use of antiplatelet agents needs further evaluation in prospective randomized trials.

Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention. [2011.01]
BACKGROUND: There is no head-to-head comparison between tirofiban versus eptifibatide in patients undergoing percutaneous coronary intervention (PCI) when added to standard antiaggregating drugs (AAD) to prevent ischemic events within 1 year... CONCLUSION: Head-to-head comparison between eptifibatide and tirofiban in patients undergoing PCI while on double AAD showed that eptifibatide had a lower efficacy on the incidence of composite ischemic events within 1 year, which might be explained by a reduced action on CK-MB pre-PCI.

Comparison of Ecchymosis Rates With Measurement of Automated and Manual Blood Pressures in Patients Receiving Eptifibatide Therapy. [2010.12.01]
CONCLUSIONS:: In 44 post-coronary interventional procedure patients on eptifibatide therapy, ecchymosis occurred in 9% of arms with automated BP measurement and 14% of arms with manual BP measurement during the 24-hour study period. This difference was not statistically significant. No other complications were observed. This study found that the overall incidence of complications from BP measurement was low and not related to whether the device used was an automated or manual BP device in post-coronary interventional procedure patients on eptifibatide therapy. Based on this study and a prior one, the reluctance of clinicians to use automated BP devices in post-procedural coronary intervention patients because of fears of increased tissue bleeding does not appear scientifically justified.

more studies >>

Clinical Trials Related to Integrilin (Eptifibatide)

A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks [Terminated]
The main purpose of this research study is to try to improve the results of the standard treatment for heart attacks. Normally, heart attack patients get a fast dose and a slow dose of eptifibatide in the emergency room, shortly after arriving. This drug is usually given through a vein in the arm. However, eptifibatide can also be injected directly into the heart's blood supply just before angioplasty, a common procedure to unblock a blood vessel in the heart. This new way of giving the drug is being studying.

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR) [Completed]
The primary goal of this trial is to determine if individuals with acute ischemic stroke treated with a full dose of IV recombinant tissue plasminogen activator (rt-PA) plus IV eptifibatide started within 3 hours of symptom onset are more likely to have a better outcome than individuals treated with standard IV rt-PA alone.

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke [Completed]
The primary goal of this trial is to determine if individuals with acute ischemic stroke treated with a medium dose of IV rt-PA plus IV eptifibatide started within 3 hours of symptom onset are more likely to have a better outcome than individuals treated with standard IV rt-PA alone.

A Safety Study of Eptifibatide in Patients With Sickle Cell Disease [Terminated]
This study will evaluate the safety of eptifibatide in sickle cell patients and how well it works during the course of painful crises. The overall hypothesis that we seek to test is that increased platelet activation and the resultant inflammatory responses are important contributors to the problems of sickle cell disease. Sickle cell disease has been referred to both as a condition associated with increased risk of blood clots and increased inflammation. A painful crisis represents the most common cli nical problem in sickle cell disease, but the treatment of these crises remains inadequate.

EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) [Completed]
The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed provisional use of eptifibatide).

more trials >>

Reports of Suspected Integrilin (Eptifibatide) Side Effects

Thrombocytopenia (15)Haemoptysis (5)Haemorrhage (4)Death (4)Cardiogenic Shock (3)Endotracheal Intubation (3)Anaphylactic Shock (2)Pyrexia (2)Peripheral Ischaemia (2)Blood Culture Positive (2)more >>


Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015